NEWS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
7th Annual Truist Securities Life Sciences Summit – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer
SOUTH SAN FRANCISCO, Calif., April 20, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
20th Annual Needham Virtual Healthcare Conference – Presentation
Webcast, Click Here Download Presentation, Click Here
Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
– Initiation of an IND enabling toxicology study for the first program under the 2018 collaboration oncytokine derivatives earns a $15 million milestone payment from Merck SOUTH SAN FRANCISCO, Calif., April 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a...
Sutro Biopharma to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., April 8, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...
Open Letter from CEO, Bill Newell
I Stand in Support of our AAPI Community I want to address the violence and discrimination towards our AAPI community; it has been there for hundreds of years. It is now apparent that it was, in some cases, under-reported or ignored. Most certainly it was greatly...
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March. 22, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer...
Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones
- Year-end 2020 cash, cash equivalents and marketable securities of $326.5 million, with projected runway into the second half of 2023 - Four antibody-drug conjugate programs are now in the clinic that were discovered through Sutro’s proprietary and integrated...
Sutro Biopharma Presents at the 11th Annual World ADC Europe 2021 – PowerPoint Presentation
Download the presentation, CLICK HERE
Bill Newell, CEO Interviewed by Biotech 2050
Episode 47. Next Generation Cell Free Cancer and Autoimmune Therapeutics, Bill Newell, CEO, Sutro Biopharma